The debate over three controversial arthritis drug is over.
Now, the F-D-A must make its decision.
Two stories on prescription drug use top the news tonight
Earlier today, an advisory board to the Food and Drug Adminstration recommended approving the use of three popular but controversial arthritis drugs.... Vioxx, Celebrex, and Bextra.
The F-D-A is expected to follow the recommendation.
The drugs are among those that people are currently buying from Canadian pharmacies on the internet, to try to save money.
In team coverage tonight, News Channel 8's Terri Russell reveals why you may not be getting what you ordered from a Canadian supplier.
In the F-D-A hearing, the panelists were unanimous in saying the drugs all pose risks of heart trouble, but that Vioxx should return to the market. The other two should stay on the market...all with stricter warnings called "black boxes."
Good news to some patients and doctors who believe the benefits
The amount of money represented is staggering.
For example, in the first half of 2003, sales of Celebrex totaled one-point six billion dollars, with vioxx and one-point one billion, and bextra at 700-thousand dollars.
For a total of close to three and a half billion dollars.
If you're one of the 20 million Americans who suffer from Arthritis pain, you may wonder why one drug works for you, but not the other two, even though they are all in the family of cox-2 inhibitors.